Curiosity is often described as a soft skill. It is not. It is a competitive weapon. The professionals who ask better questions see more...
How Curiosity Can Open Doors You Didn’t Even Know Existed
read more
INSIGHTS ON PHARMA INNOVATION, ETHICS, AND LEADERSHIP
Explore thought leadership articles and stories shaping the future.
Latest Insights
Why Payer Relationships Matter More Than Pricing Strategy
Pricing strategies get plenty of attention in pharma. Teams hold workshops, hire consultants, and produce slide decks that look increasingly complex...
The Real Reason Market Access Planning Fails Before Launch
Market access is one of those phrases that looks perfect on a slide deck. It sounds strategic, sophisticated, and forward-thinking. Yet, when you...
The Biggest Access Lesson I’ve Learned in 20+ Years — And Why It Is Still Relevant
After two decades in pharma and market access, I’ve seen launches succeed spectacularly, stumble unexpectedly, and sometimes collapse entirely....
What Pharma Can Learn About Access Strategy from Tech and Consumer Industries
Pharma often treats access as a regulatory hurdle: tick the box, submit the dossier, wait for approval, and hope payers follow. Tech and consumer...
Why ‘Value Stories’ Fail to Resonate with Payers — And How to Make Them Stick
Pharma teams spend months crafting “value stories.” They’re sleek, glossy, and full of optimism. They highlight innovation, unmet need, and...
The One Question Pharma Teams Forget to Ask Before Launch: “Who Loses If We Win?”
Every launch team asks: “Who benefits if we succeed?” Patients, shareholders, and sometimes physicians all make the list. But very few ask the...
Market Access Myths That Cost Companies Millions
Market access is littered with myths that sound plausible — until they quietly drain millions from your launch budget. Believing them isn’t just...
The Toughest Stakeholder to Align in Market Access (Hint: It’s Not Who You Think)
When people talk about “tough stakeholders” in market access, the usual suspects are regulators, HTA bodies, and payers. Challenging? Absolutely....
Why “Patient Centricity” Often Fails in Practice — and What True Patient Focus Looks Like
“Patient centricity” is everywhere in pharma these days. Let’s resist the temptation to name the consultancy behind this ubiquitous and...
The Hidden Reason Most Drug Launches Underperform (and How to Fix It)
Pharma loves a good launch. They invest billions. They polish the slides meticulously. A new medicine hits the market with the same excitement as...
The Role of Trust and Transparency in AI-driven Healthcare
Artificial intelligence is rewriting the possibilities of healthcare. From early diagnosis to personalised treatment and operational efficiency, its...
Localising Global Access Strategy in Emerging Markets
Global access strategies often sound impressive on paper — harmonised pricing frameworks, centralised value dossiers, and global evidence plans. But...